Pharmarise Holdings Management

Management criteria checks 2/4

Pharmarise Holdings' CEO is Toshimichi Ohno, appointed in Aug 2016, has a tenure of 7.75 years. directly owns 29.45% of the company’s shares, worth ¥2.14B. The average tenure of the management team and the board of directors is 7.8 years and 7.8 years respectively.

Key information

Toshimichi Ohno

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	7.8yrs
CEO ownership	29.5%
Management average tenure	7.8yrs
Board average tenure	7.8yrs

Recent management updates

Recent updates

Pharmarise Holdings' (TSE:2796) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 22

Pharmarise Holdings (TSE:2796) Is Paying Out A Larger Dividend Than Last Year

Mar 07

CEO

Toshimichi Ohno (71 yo)

7.8yrs

Tenure

Mr. Toshimichi Ohno has been Chairman and Chief Executive Officer of Pharmarise Holdings Corporation since August 2016 and served as its President since June 1984. Mr. Ohno served as Senior Managing Direct...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Toshimichi Ohno	Chairman of the Board & CEO	7.8yrs	no data	29.45% ¥ 2.1b
Masayuki Akiyama	President	5.8yrs	no data	0.30% ¥ 22.1m
Keiko Matsuura	Senior MD & Director	14.7yrs	no data	0.36% ¥ 26.5m

7.8yrs

Average Tenure

68yo

Average Age

Experienced Management: 2796's management team is seasoned and experienced (7.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Toshimichi Ohno	Chairman of the Board & CEO	39.9yrs	no data	29.45% ¥ 2.1b
Masayuki Akiyama	President	no data	no data	0.30% ¥ 22.1m
Keiko Matsuura	Senior MD & Director	14.7yrs	no data	0.36% ¥ 26.5m
Sayoko Ohno	Vice Chairman of the Board	34.8yrs	no data	3.71% ¥ 270.0m
Yoshio Odaka	Full-Time Audit & Supervisory Board Member	7.8yrs	no data	0.16% ¥ 11.6m
Hiroshi Kanno	Director	3.8yrs	no data	0.064% ¥ 4.6m
Norio Watanabe	Independent External Director	8.8yrs	no data	0.024% ¥ 1.7m
Hiromu Tada	Independent External Director	7.8yrs	no data	no data
Yutaka Numata	Director	5.8yrs	no data	0.037% ¥ 2.7m
Ichijo Toda	Independent External Director	3.8yrs	no data	no data
Tsuneo Sonobe	Outside Audit & Supervisory Board Member	3.8yrs	no data	no data
Takayuki Enomoto	Outside Audit & Supervisory Board Member	6.7yrs	no data	no data

7.8yrs

Average Tenure

68yo

Average Age

Experienced Board: 2796's board of directors are considered experienced (7.8 years average tenure).

Pharmarise Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

Pharmarise Holdings Corporation, Annual General Meeting, Aug 30, 2023

Less than half of directors are independent

Pharmarise Holdings Corporation, Annual General Meeting, Aug 25, 2022

Less than half of directors are independent

Recent updates

Pharmarise Holdings Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024

New minor risk - Financial position

Third quarter 2024 earnings released: JP¥8.36 loss per share (vs JP¥14.43 profit in 3Q 2023)

Pharmarise Holdings' (TSE:2796) Shareholders Will Receive A Bigger Dividend Than Last Year

Pharmarise Holdings (TSE:2796) Is Paying Out A Larger Dividend Than Last Year

Pharmarise Holdings Corporation to Report Q3, 2024 Results on Mar 25, 2024

Pharmarise Holdings Corporation (TSE:2796) entered into stock transfer agreement to acquire GOOD AID Inc. from Kotoshino Co., Ltd. and Yuta Hattori.

Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024

Second quarter 2024 earnings released: EPS: JP¥15.10 (vs JP¥4.15 loss in 2Q 2023)

New minor risk - Shareholder dilution

Pharmarise Holdings Corporation to Report Q2, 2024 Results on Dec 25, 2023

Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024

Pharmarise Holdings Corporation Provides Dividend Guidance for the Fiscal Year Ending May 31, 2024

First quarter 2024 earnings released: EPS: JP¥13.05 (vs JP¥11.87 in 1Q 2023)

Full year 2023 earnings released: EPS: JP¥35.42 (vs JP¥47.90 in FY 2022)

Pharmarise Holdings Corporation to Report Q1, 2024 Results on Oct 11, 2023

Full year 2023 earnings released: EPS: JP¥35.42 (vs JP¥47.90 in FY 2022)

Pharmarise Holdings Corporation Announces Commemorative Dividend for the Fiscal Year Ending May 31, 2024

Pharmarise Holdings Corporation, Annual General Meeting, Aug 30, 2023

Pharmarise Holdings Corporation to Report Fiscal Year 2023 Results on Jul 11, 2023

Upcoming dividend of JP¥14.00 per share at 2.2% yield

Third quarter 2023 earnings released: EPS: JP¥14.43 (vs JP¥7.70 in 3Q 2022)

Pharmarise Holdings Corporation (TSE:2796) entered into basic agreement to acquire Two Dispensing Pharmacies in Mie Prefecture.

Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Full Year of Fiscal Year Ending May 31, 2023

Second quarter 2023 earnings released: JP¥4.15 loss per share (vs JP¥20.05 profit in 2Q 2022)

Pharmarise Holdings Corporation to Report Q2, 2023 Results on Dec 29, 2022

Less than half of directors are independent

First quarter 2023 earnings released: EPS: JP¥11.87 (vs JP¥6.78 in 1Q 2022)

Pharmarise Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months and Full Year of Fiscal Year Ending May 31, 2023

Pharmarise Holdings Corporation to Report Q1, 2023 Results on Oct 13, 2022

Pharmarise Holdings Corporation Announces Cash Dividend for the Year Ended May 31, 2022, Payable on August 26, 2022; Provides Dividend Guidance for the Year Ending May 31, 2023

Pharmarise Holdings Corporation, Annual General Meeting, Aug 25, 2022

Full year 2022 earnings released: EPS: JP¥47.90 (vs JP¥45.78 in FY 2021)

Pharmarise Holdings Corporation (TSE:2796) agreed to acquire Two Dispensing Pharmacies.

Pharmarise Holdings Corporation to Report Fiscal Year 2022 Results on Jul 08, 2022

Upcoming dividend of JP¥14.00 per share

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: JP¥7.70 (vs JP¥1.40 loss in 3Q 2021)

Pharmarise Holdings Corporation to Report Q3, 2022 Results on Apr 12, 2022

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

First quarter 2022 earnings released: EPS JP¥6.78 (vs JP¥5.93 loss in 1Q 2021)

Full year 2021 earnings released: EPS JP¥45.78 (vs JP¥61.03 in FY 2020)

Upcoming dividend of JP¥14.00 per share

Third quarter 2021 earnings released: JP¥1.40 loss per share (vs JP¥11.69 profit in 3Q 2020)

Pharmarise Holdings Corporation to Report Q3, 2021 Results on Apr 14, 2021

Second quarter 2021 earnings released: EPS JP¥19.54

Pharmarise Holdings Corporation to Report Q2, 2021 Results on Jan 14, 2021

Pharmarise Holdings Corporation to Report Q1, 2021 Results on Oct 15, 2020

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age